Comparative Efficacy and Safety of Tislelizumab in Second-Line Esophageal Squamous Cell Carcinoma: Systematic Literature Review and Simulated Treatment Comparisons.

Adv Ther · 2026 · PMC12909357 · PMID 41335329

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

It is also crucial to note that most comparisons did not reach statistical significance, which may be partly due to the reduced statistical power inherent in population-adjustment methods and the wide confidence intervals.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.